Related Experiment Video
Updated: Jun 19, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
The Role and Implications of COVID-19 in Incident and Prevalent Heart Failure
Juan Simon Rico-Mesa1, Justin Haloot2, B K Anupama2
1Department of Cardiology, Johns Hopkins Medicine, Baltimore, MD, USA.
Insights
COVID-19 significantly worsens heart failure outcomes, increasing severity and mortality through mechanisms like cytokine storms and thrombosis. Survivors face long-term cardiovascular risks, necessitating further research for better management.
Area of Science:
- Cardiology
- Infectious Diseases
- Pathophysiology
Background:
- COVID-19 poses significant risks to cardiovascular health.
- Pre-existing heart failure complicates COVID-19 prognosis.
Purpose of the Study:
- To review the pathophysiological interactions between COVID-19 and heart failure.
- To elucidate mechanisms driving worse outcomes in COVID-19 patients with heart failure.
Main Methods:
- Literature review of pathophysiological interactions.
- Analysis of mechanisms exacerbating heart failure during COVID-19.
Main Results:
- Heart failure patients experience severe COVID-19 symptoms and higher mortality.
- Mechanisms include cytokine storms, myocardial infarction, myocarditis, and thrombosis.
- Elevated cardiac biomarkers (troponin, natriuretic peptides) indicate severe disease.
- Long-term risks for survivors include new heart failure, cardiomyopathy, and cardiac arrest.
Conclusions:
- COVID-19 severely impacts patients with pre-existing heart failure.
- Ongoing research is crucial for targeted therapies and improved management.
- Better prevention, diagnosis, and treatment strategies are needed for heart failure in the context of COVID-19.
Purpose Of Review:
This review examines the pathophysiological interactions between COVID-19 and heart failure, highlighting the exacerbation of heart failure in COVID-19 patients. It focuses on the complex mechanisms driving worse outcomes in these patients.
Recent Findings:
Patients with pre-existing heart failure experience more severe symptoms and higher mortality rates due to mechanisms such as cytokine storms, myocardial infarction, myocarditis, microvascular dysfunction, thrombosis, and stress cardiomyopathy. Elevated biomarkers like troponin and natriuretic peptides correlate with severe disease. Long-term cardiovascular risks for COVID-19 survivors include increased incidence of heart failure, non-ischemic cardiomyopathy, cardiac arrest, and cardiogenic shock. COVID-19 significantly impacts patients with pre-existing heart failure, leading to severe symptoms and higher mortality. Elevated cardiac biomarkers are indicators of severe disease. Acute and long-term cardiovascular complications are common, calling for ongoing research into targeted therapies and improved management strategies to better prevent, diagnose, and treat heart failure in the context of COVID-19.
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics

